Trials / Unknown
UnknownNCT00053560
To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids
A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 155 (planned)
- Sponsor
- Genelabs Technologies · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with glucocorticoids (e.g., prednisone).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prasterone (GL701) |
Timeline
- Start date
- 2002-12-01
- Completion
- 2004-08-01
- First posted
- 2003-02-03
- Last updated
- 2008-01-07
Locations
26 sites across 2 countries: United States, Mexico
Source: ClinicalTrials.gov record NCT00053560. Inclusion in this directory is not an endorsement.